Kezar Life Sciences to Participate in Three Upcoming Investor Conferences
31 Agosto 2023 - 10:01PM
Business Wire
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage
biotechnology company discovering and developing breakthrough
treatments for immune-mediated and oncologic disorders, today
announced that the Company will participate in three upcoming
investor conferences taking place in September:
- Event: 2023 Wells Fargo Healthcare Conference
Location: Boston, MA Date/Time: Thursday, September
7, 2023, at 12:45 pm ET Presenter: Noreen R. Henig, M.D.,
Chief Medical Officer Format: Fireside Chat
- Event: Morgan Stanley 21st Annual Global Healthcare
Conference Location: New York, NY Date/Time: Tuesday,
September 12, 2023, at 10:50 am ET Presenter: John Fowler,
Co-Founder and Chief Executive Officer Format: Fireside
Chat
- Event: H.C. Wainwright 25th Annual Global Investment
Conference Location: New York, NY Date/Time:
Wednesday, September 13, 2023, at 12:30 pm ET Presenter:
John Fowler, Co-Founder and Chief Executive Officer Format:
Podium Presentation
Webcasts from the presentations will be available on the “Events
& Presentations” section of the Company’s website at
www.kezarlifesciences.com. Following the events, archived webcasts
will be available on the Kezar website for 90 days.
About Kezar Life Sciences
Kezar Life Sciences is a clinical-stage biopharmaceutical
company discovering and developing novel treatments for
immune-mediated and oncologic disorders. The company is pioneering
first-in-class, small-molecule therapies that harness master
regulators of cellular function to inhibit multiple drivers of
disease via single, powerful targets. Zetomipzomib, its lead
development asset, is a selective immunoproteasome inhibitor that
has completed a Phase 2 clinical trial in lupus nephritis. This
product candidate also has the potential to address multiple
chronic immune-mediated diseases. KZR-261 is the first anti-cancer
clinical candidate from the company’s platform targeting the Sec61
translocon and the protein secretion pathway. An open-label
dose-escalation Phase 1 clinical trial of KZR-261 to assess safety,
tolerability and preliminary tumor activity in solid tumors is
underway. For more information, visit www.kezarlifesciences.com and
follow us on LinkedIn, Facebook, Twitter and Instagram.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230831496066/en/
Investor Contact: Gitanjali Jain Vice President, Investor
Relations and External Affairs gjain@kezarbio.com
Media Contact: Will Zasadny Evoke Canale
will.zasadny@evokegroup.com
Grafico Azioni Kezar Life Sciences (NASDAQ:KZR)
Storico
Da Dic 2024 a Gen 2025
Grafico Azioni Kezar Life Sciences (NASDAQ:KZR)
Storico
Da Gen 2024 a Gen 2025